<DOC>
	<DOC>NCT00000178</DOC>
	<brief_summary>This is a randomized placebo controlled, double blind study. Patients who meet eligibility criteria and decide to participate in the study will be randomly assigned to receive either drug treatment or a placebo. Neither the patients nor the participating investigators will know who is receiving the drugs and who is receiving the placebo. Participation involves 15 outpatient clinic visits over a 68 week period. Patients take study medication at varying doses (the maximum dose is 20 mg daily), along with calcium and vitamin supplements.</brief_summary>
	<brief_title>Multicenter Trial of Prednisone in Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Patients with Alzheimer's disease who are in stable medical condition Patients with diabetes or severe osteoporosis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2005</verification_date>
	<keyword>Alzheimer's disease</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Anti-inflammatory agents</keyword>
</DOC>